Iovance Biotherapeutics
IOVA
84 hedge funds and large institutions have $349M invested in Iovance Biotherapeutics in 2017 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 30 reducing their positions, and 9 closing their positions.
1,745% more call options, than puts
Call options by funds: $3.43M | Put options by funds: $186K
76.4% more ownership
Funds ownership: 0% → 76.4% (+76%)
44% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 9
4% more funds holding
Funds holding: 81 → 84 (+3)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3% less capital invested
Capital invested by funds: $361M → $349M (-$11.8M)
13% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$6.92M |
| 2 |
PA
Perceptive Advisors
New York
|
+$5.06M |
| 3 |
Millennium Management
New York
|
+$2.65M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$1.07M |
| 5 |
NFA
Nationwide Fund Advisors
Columbus,
Ohio
|
+$681K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.41M |
| 2 |
QF
QVT Financial
New York
|
-$4.61M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$4.13M |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$2.56M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
-$2.54M |
IOVA Hedge Fund Activity: Q2 2017 in Review
84 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q2 2017, worth a combined $349M — down 3.3% from $361M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new IOVA positions and 9 closed out — a net gain of 4 holders — while 26 added to existing stakes and 30 trimmed.
The largest buyer was JP Morgan Chase, opening a new position worth an estimated $6.92M. The largest seller was Fidelity Investments, cutting an estimated $6.41M.
- 84 institutional investors held Iovance Biotherapeutics (IOVA) as of Q2 2017, up from 81 in Q1 2017.
- Funds reported $349M of Iovance Biotherapeutics stock for Q2 2017, down 3.3% quarter-over-quarter.
- 13 funds opened new Iovance Biotherapeutics positions in Q2 2017 and 9 closed out, a net change of +4 holders.
- The largest Iovance Biotherapeutics buyer in Q2 2017 was JP Morgan Chase, an estimated $6.92M added.
- The largest Iovance Biotherapeutics seller in Q2 2017 was Fidelity Investments, an estimated $6.41M sold.
Based on aggregated 13F filings for Q2 2017.